Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | INSR | P06213 | 4/20 | 0.41 |
| ▸ | MET | P08581 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016592 | 0.99 | MAP3K7 (0.43) | MAP3K7SYKBRD4BTKINSR | |
| SCHEMBL1474148 | 0.87 | CCNT1 (0.49) | SYKBRD4JAK1MAPTPOLB | |
| SCHEMBL1474556 | 0.83 | BRD4 (0.50) | SYKBRD4INSRMETJAK1 | |
| SCHEMBL1474812 | 0.82 | JAK3 (0.54) | SYKBRD4BTKINSRMET | |
| SCHEMBL1476475 | 0.81 | ALK (0.49) | SYKBRD4BTKINSRMET | |
| SCHEMBL1473803 | 0.81 | EGFR (0.44) | SYKBRD4INSRMETJAK1 | |
| SCHEMBL3120100 | 0.81 | BRD4 (0.65) | MAP3K7BRD4BTKMETALK | |
| SCHEMBL1476326 | 0.81 | EGFR (0.42) | SYKBRD4INSRMETALK | |
| SCHEMBL5013236 | 0.81 | POLB (0.49) | SYKBRD4BTKINSRMET | |
| SCHEMBL1474659 | 0.80 | JAK3 (0.55) | SYKBRD4BTKINSRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAP3K7 29/4885SYK 62/4885BRD4 538/4885 |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | MAP3K7 108/4885SYK 233/4885BRD4 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.